CYBERDYNE Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Yoshiyuki Sankai

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	18.8yrs
Eigendom CEO	38.2%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	14.6yrs

Recente managementupdates

Recent updates

CEO

Yoshiyuki Sankai (66 yo)

18.8yrs

Tenure

Dr. Yoshiyuki Sankai has been the President and Chief Executive Officer of CYBERDYNE Inc. since February 2006 and also serves as its Chairman. Dr. Sankai established CYBERDYNE, Inc. in June 2004. He has be...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yoshiyuki Sankai	Chairman	20.4yrs	geen gegevens	38.24% € 91.1m
Shinji Honda	Executive Director & COO	1.4yrs	geen gegevens	0.0095% € 22.6k
Shinji Uga	Head of Corporate Department & Director	15.8yrs	geen gegevens	geen gegevens
Cees Vellekoop	Outside Audit & Supervisory Board Member	17.4yrs	geen gegevens	0.0047% € 11.3k
Hikari Imai	Independent Outside Director	9.4yrs	geen gegevens	geen gegevens
Kenichiro Okamura	Independent Outside Audit & Supervisory Board Member	13.4yrs	geen gegevens	geen gegevens
Hiroaki Kawamoto	Director	20.4yrs	geen gegevens	geen gegevens
Yutaka Fujitani	Independent Outside Audit & Supervisory Board Member	13.4yrs	geen gegevens	geen gegevens
Akira Matsumura	Independent Outside Director	no data	geen gegevens	0.0024% € 5.6k

14.6yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 8C4 zijn ervaren en ervaren (gemiddelde ambtstermijn van 14.6 jaar).

CYBERDYNE Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

CYBERDYNE Inc., Annual General Meeting, Jun 22, 2023

Cyberdyne Inc. Announces Yuzo Toda Passed Away on December 27, 2022, and Retired from the Position of Director on the Same Day

Less than half of directors are independent

CYBERDYNE Inc., Annual General Meeting, Jun 30, 2022

Less than half of directors are independent

CYBERDYNE Inc., Annual General Meeting, Jun 24, 2021

Recent updates

CYBERDYNE Inc. to Report First Half, 2025 Results on Nov 14, 2024

First quarter 2025 earnings released: EPS: JP¥0.052 (vs JP¥1.56 in 1Q 2024)

Now 21% overvalued after recent price rise

Full year 2024 earnings released: JP¥6.99 loss per share (vs JP¥1.39 loss in FY 2023)

Forecast breakeven date pushed back to 2026

CYBERDYNE Inc. to Report Q1, 2025 Results on Aug 14, 2024

New minor risk - Share price stability

Full year 2024 earnings released: JP¥6.99 loss per share (vs JP¥1.39 loss in FY 2023)

U.S. FDA Becomes the world's First to Clear Smaller Model of Medical HAL and Expanded Indication for Cerebral Palsy

U.S. FDA Becomes the world's First to Clear Smaller Model of Medical HAL and Expanded Indication for Cerebral Palsy

CYBERDYNE Inc. to Report Fiscal Year 2024 Results on May 15, 2024

Third quarter 2024 earnings released: JP¥1.65 loss per share (vs JP¥0.93 loss in 3Q 2023)

New minor risk - Share price stability

CYBERDYNE Inc. to Report Q3, 2024 Results on Feb 14, 2024

Forecast breakeven date pushed back to 2026

Second quarter 2024 earnings released: JP¥4.42 loss per share (vs JP¥0.13 profit in 2Q 2023)

CYBERDYNE Inc. to Report Q2, 2024 Results on Nov 14, 2023

CYBERDYNE Inc. to Report First Half, 2024 Results on Nov 14, 2023

First quarter 2024 earnings released: EPS: JP¥1.56 (vs JP¥1.12 in 1Q 2023)

CYBERDYNE Inc. to Report Q1, 2024 Results on Aug 14, 2023

New minor risk - Share price stability

Forecast breakeven date pushed back to 2025

Full year 2023 earnings released: JP¥1.39 loss per share (vs JP¥2.29 loss in FY 2022)

Forecast breakeven date pushed back to 2026

CYBERDYNE Inc., Annual General Meeting, Jun 22, 2023

CYBERDYNE Inc. to Report Fiscal Year 2023 Results on May 15, 2023

Third quarter 2023 earnings released: JP¥0.93 loss per share (vs JP¥0.74 loss in 3Q 2022)

CYBERDYNE Inc. to Report Q3, 2023 Results on Feb 14, 2023

Cyberdyne Inc. Announces Yuzo Toda Passed Away on December 27, 2022, and Retired from the Position of Director on the Same Day

Less than half of directors are independent

CYBERDYNE Inc. to Report First Half, 2023 Results on Nov 14, 2022

First quarter 2023 earnings released: EPS: JP¥1.13 (vs JP¥1.28 loss in 1Q 2022)

CYBERDYNE Inc. to Report Q1, 2023 Results on Aug 12, 2022

Full year 2022 earnings released: JP¥2.29 loss per share (vs JP¥0.27 loss in FY 2021)

Forecast breakeven date pushed back to 2025

CYBERDYNE Inc., Annual General Meeting, Jun 30, 2022

Less than half of directors are independent

Now 23% undervalued after recent price drop

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

CYBERDYNE Inc. to Report Fiscal Year 2022 Results on May 13, 2022

Forecast breakeven date pushed back to 2023

Second quarter 2022 earnings released: JP¥0.70 loss per share (vs JP¥1.38 profit in 2Q 2021)

Forecast to breakeven in 2022

CYBERDYNE Inc. Announces Medical HAL Single Joint Type Receives Medical Device Approval from Australian Therapeutic Goods Administration, Department of Health

CYBERDYNE Inc. (TSE:7779) acquired C2,Inc.

First quarter 2022 earnings released: JP¥1.28 loss per share (vs JP¥0.60 loss in 1Q 2021)

Cyberdyne Inc. Preliminary Results of Medical Hal Lower Limb Type Stroke Clinical Trial

Forecast breakeven moved forward to 2022

Full year 2021 earnings released: JP¥0.27 loss per share (vs JP¥0.71 loss in FY 2020)

New 90-day low: €4.96

CYBERDYNE Inc., Annual General Meeting, Jun 24, 2021

CYBERDYNE Inc Forms Strategic Partnership with Cellsource Co., Ltd

Third quarter 2021 earnings released: JP¥0.40 loss per share (vs JP¥0.46 profit in 3Q 2020)

Revenue misses expectations

New 90-day low: €5.00

CYBERDYNE Inc. to Report Q3, 2021 Results on Feb 12, 2021

CYBERDYNE Inc. Medical Hal Obtains Approval from Singapore Health Science Authority

CYBERDYNE Inc. Announces that Stroke Clinical Trial on Medical HAL is Complete

Cyberdyne Inc. Exports Six Units of Its Wearable Cyborg Hal (Three Units of Lower Limb Type, Two Units of Single Joint Type, One Unit of Lumbar Type) to Institute of Brain & Spine Hospital

New 90-day high: €6.75

Second quarter 2021 earnings released: EPS JP¥1.38

Revenue beats expectations

CYBERDYNE Inc. Obtains a Medical Device Approval for HAL for Medical Use Lower Limb Type

Malaysian Public Social Security Organization Expands Cybernics Treatment to 4 Major Sites in Malaysia

CYBERDYNE Inc. to Report Q2, 2021 Results on Nov 13, 2020

New 90-day high: €5.25

CYBERDYNE Inc. Announces Marketing Clearance From U.S. FDA for Medical HAL Expands To Stroke And Progressive Neuromuscular Disease

New 90-day high - €4.00

First quarter earnings released